 Home > Medical News > Latest Medical News > Drugs facing an important review decision by the U.S. FDA in July 2021

Drugs facing an important review decision by the U.S. FDA in July 2021

 Last Update: 2021-08-16
 Source: Internet
 Author: User

Tags

beta amyloid alzheimer

organizational decision making

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

In the first half of this year, the US FDA approved a total of 27 innovative drugs, and three (Brexafemme, Aduhelm, Rylaze) were approved in June

Among them, the anti-beta amyloid antibody drug Aduhelm is the first new drug to treat Alzheimer's disease (AD) in the past 20 years

Entering July, a number of drugs will usher in an important review decision by the FDA

Reference source: Biotech Stocks Facing FDA Decision In July 2021

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.